within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF01_Nivolumab;

model Nivolumab
  extends Pharmacolibrary.Drugs.ATC.L.L01FF01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01FF01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Nivolumab is a fully human IgG4 monoclonal antibody that inhibits the programmed death-1 (PD-1) immune checkpoint pathway. It is approved for the treatment of various cancers, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, and others. Nivolumab enhances anti-tumor immune responses by blocking PD-1 receptor from binding to its ligands, PD-L1 and PD-L2.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were obtained from studies in adult patients with cancer, both male and female, across different tumor types. Data primarily reflect intravenous administration in clinical trial populations.</p><h4>References</h4><ol><li><p>Albiges, L, et al., &amp; George, S (2025). Subcutaneous versus intravenous nivolumab for renal cell carcinoma. <i>Annals of oncology : official journal of the European Society for Medical Oncology</i> 36(1) 99–107. DOI:<a href=\"https://doi.org/10.1016/j.annonc.2024.09.002\">10.1016/j.annonc.2024.09.002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39288844/\">https://pubmed.ncbi.nlm.nih.gov/39288844</a></p></li><li><p>Davis, KL, et al., &amp; Mackall, CL (2020). Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. <i>The Lancet. Oncology</i> 21(4) 541–550. DOI:<a href=\"https://doi.org/10.1016/S1470-2045(20)30023-1\">10.1016/S1470-2045(20)30023-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32192573/\">https://pubmed.ncbi.nlm.nih.gov/32192573</a></p></li><li><p>Brahmer, JR, et al., &amp; Topalian, SL (2010). Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 28(19) 3167–3175. DOI:<a href=\"https://doi.org/10.1200/JCO.2009.26.7609\">10.1200/JCO.2009.26.7609</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20516446/\">https://pubmed.ncbi.nlm.nih.gov/20516446</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Nivolumab;
